KR20250048594A - 면역자극성 올리고뉴클레오티드 - Google Patents

면역자극성 올리고뉴클레오티드 Download PDF

Info

Publication number
KR20250048594A
KR20250048594A KR1020257009617A KR20257009617A KR20250048594A KR 20250048594 A KR20250048594 A KR 20250048594A KR 1020257009617 A KR1020257009617 A KR 1020257009617A KR 20257009617 A KR20257009617 A KR 20257009617A KR 20250048594 A KR20250048594 A KR 20250048594A
Authority
KR
South Korea
Prior art keywords
oligonucleotide
immunostimulatory
immunostimulatory oligonucleotide
cholesteryl
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257009617A
Other languages
English (en)
Korean (ko)
Inventor
토마스 일크
Original Assignee
엘랑코 애니멀 헬스 게엄베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘랑코 애니멀 헬스 게엄베하 filed Critical 엘랑코 애니멀 헬스 게엄베하
Publication of KR20250048594A publication Critical patent/KR20250048594A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257009617A 2017-12-15 2018-12-07 면역자극성 올리고뉴클레오티드 Pending KR20250048594A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP17207750 2017-12-15
EP17207740 2017-12-15
EP17207750.5 2017-12-15
EP17207746 2017-12-15
EP17207740.6 2017-12-15
EP17207746.3 2017-12-15
PCT/EP2018/084019 WO2019115402A1 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides
KR1020207020349A KR102787688B1 (ko) 2017-12-15 2018-12-07 면역자극성 올리고뉴클레오티드

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207020349A Division KR102787688B1 (ko) 2017-12-15 2018-12-07 면역자극성 올리고뉴클레오티드

Publications (1)

Publication Number Publication Date
KR20250048594A true KR20250048594A (ko) 2025-04-09

Family

ID=66818991

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020257009617A Pending KR20250048594A (ko) 2017-12-15 2018-12-07 면역자극성 올리고뉴클레오티드
KR1020207020350A Pending KR20200099556A (ko) 2017-12-15 2018-12-07 면역자극성 조성물
KR1020207020351A Ceased KR20200098638A (ko) 2017-12-15 2018-12-07 면역자극성 올리고뉴클레오티드
KR1020207020349A Active KR102787688B1 (ko) 2017-12-15 2018-12-07 면역자극성 올리고뉴클레오티드

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020207020350A Pending KR20200099556A (ko) 2017-12-15 2018-12-07 면역자극성 조성물
KR1020207020351A Ceased KR20200098638A (ko) 2017-12-15 2018-12-07 면역자극성 올리고뉴클레오티드
KR1020207020349A Active KR102787688B1 (ko) 2017-12-15 2018-12-07 면역자극성 올리고뉴클레오티드

Country Status (24)

Country Link
US (7) US11542507B2 (cg-RX-API-DMAC10.html)
EP (4) EP3701032A1 (cg-RX-API-DMAC10.html)
JP (5) JP7770769B2 (cg-RX-API-DMAC10.html)
KR (4) KR20250048594A (cg-RX-API-DMAC10.html)
CN (5) CN111801116B (cg-RX-API-DMAC10.html)
AU (5) AU2018385257B2 (cg-RX-API-DMAC10.html)
BR (2) BR112020011838A2 (cg-RX-API-DMAC10.html)
CA (3) CA3085657A1 (cg-RX-API-DMAC10.html)
CL (3) CL2020001561A1 (cg-RX-API-DMAC10.html)
CO (3) CO2020007100A2 (cg-RX-API-DMAC10.html)
CR (1) CR20200260A (cg-RX-API-DMAC10.html)
DK (1) DK3700564T3 (cg-RX-API-DMAC10.html)
DO (3) DOP2020000107A (cg-RX-API-DMAC10.html)
ES (1) ES3052969T3 (cg-RX-API-DMAC10.html)
IL (3) IL274975A (cg-RX-API-DMAC10.html)
MX (4) MX2020006244A (cg-RX-API-DMAC10.html)
PE (3) PE20200933A1 (cg-RX-API-DMAC10.html)
PH (3) PH12020550903A1 (cg-RX-API-DMAC10.html)
PL (1) PL3700564T3 (cg-RX-API-DMAC10.html)
SG (3) SG11202004773SA (cg-RX-API-DMAC10.html)
TW (3) TWI911138B (cg-RX-API-DMAC10.html)
UY (3) UY38014A (cg-RX-API-DMAC10.html)
WO (3) WO2019115385A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202004317B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2021154745A1 (en) * 2020-01-27 2021-08-05 Oregon State University Gonorrhea subunit vaccine
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス-シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
CN112159814B (zh) * 2020-10-29 2023-05-16 中国农业科学院兰州兽医研究所 一种CpG寡聚脱氧核苷酸及制备与其用途
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
CN116218852A (zh) * 2023-02-22 2023-06-06 中国人民解放军陆军军医大学 一种靶向基因启动子G-四联体区域的sgRNA及其用途
CN120290549A (zh) * 2024-01-09 2025-07-11 康希诺(上海)生物研发有限公司 一种免疫刺激序列截断多聚a尾的序列构建及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719028A (en) * 1992-12-07 1998-02-17 Third Wave Technologies Inc. Cleavase fragment length polymorphism
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
IL148844A0 (en) * 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
KR100359753B1 (ko) * 1999-12-21 2002-11-09 주식회사 제넥신 면역조절능력 및 안전성이 증가되고 dG 연속서열이결합된 포스포다이에스터 CpG올리고데옥시뉴클레오티드 변형체
AU2001276371A1 (en) 2000-06-30 2002-01-14 Epigenomics Ag Method and nucleic acids for analysing the methylation of genes implicated pharmacogenomics
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
JP4874801B2 (ja) * 2003-06-11 2012-02-15 イデラ ファーマシューティカルズ インコーポレイテッド 安定化免疫調節オリゴヌクレオチド
JP4989225B2 (ja) 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ,インコーポレイテッド 核酸親油性接合体
NZ546275A (en) * 2003-10-30 2009-05-31 Coley Pharm Gmbh C-class oligonucleotides analogs with enhanced immunostimulatory potency
CA2543072A1 (en) * 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
CN1250737C (zh) * 2003-11-07 2006-04-12 深圳市未来海洋科技发展有限公司 含CpG DNA畜禽疫苗佐剂的PCR制备方法
KR100558851B1 (ko) * 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 CpG 올리고데옥시뉴클레오티드변형체
AU2005247341B2 (en) * 2004-05-06 2008-05-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
WO2006091915A2 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
EP1764108A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
US8114636B2 (en) * 2006-02-10 2012-02-14 Life Technologies Corporation Labeling and detection of nucleic acids
WO2007095316A2 (en) 2006-02-15 2007-08-23 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
CN100418583C (zh) 2006-02-21 2008-09-17 朱鸿飞 预防和治疗乳腺炎的药物组合物
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
CN102851295B (zh) * 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll 样受体调节性寡核苷酸及其用途
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
KR20100045508A (ko) 2007-08-13 2010-05-03 콜리 파마슈티칼 게엠베하 특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 rna 서열 모티프
DK2427472T3 (en) 2009-05-05 2016-09-12 Miragen Therapeutics Lipophilic polynukleotidkonjugater
CA2761736C (en) 2009-05-14 2017-09-26 Bayer Animal Health Gmbh Enhanced immune response in avian species
HRP20181039T1 (hr) 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans
CN101979542B (zh) * 2010-10-28 2011-12-28 国家兽用生物制品工程技术研究中心 含CpG基序的核酸序列的制备方法及应用
SI2654785T1 (sl) * 2010-12-22 2019-06-28 Bayer Intellectual Property Gmbh Ojačan imunski odziv pri govejih vrstah
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
JP5872684B2 (ja) * 2011-05-26 2016-03-01 インターベット インターナショナル ベー. フェー. 免疫刺激性オリゴデオキシヌクレオチド
US9315814B2 (en) * 2011-05-26 2016-04-19 Intervet Inc. Immunostimulatory oligodeoxynucleotides
JP6375289B2 (ja) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
AR091569A1 (es) 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
CA2892490A1 (en) 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
EP2992096B1 (en) 2013-05-01 2021-03-03 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
TWI535451B (zh) * 2013-07-19 2016-06-01 財團法人國家衛生研究院 CpG寡去氧核苷酸、包含其之免疫組合物及組合物用於製備治療以刺激免疫反應的藥物之用途
AR097029A1 (es) 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
GB2517700A (en) * 2013-08-27 2015-03-04 Lgc Ltd Oligonucleotides comprising a secondary structure and uses thereof
CA2940794C (en) * 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
WO2017139570A1 (en) 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne

Also Published As

Publication number Publication date
PE20200933A1 (es) 2020-09-17
SG11202004773SA (en) 2020-06-29
US11932857B2 (en) 2024-03-19
WO2019115386A9 (en) 2020-07-23
CA3085575A1 (en) 2019-06-20
ZA202004317B (en) 2023-05-31
RU2020122545A3 (cg-RX-API-DMAC10.html) 2022-05-04
US20250215439A1 (en) 2025-07-03
EP3701032A1 (en) 2020-09-02
DOP2020000113A (es) 2020-08-31
TWI821224B (zh) 2023-11-11
ES3052969T3 (en) 2026-01-16
JP7273040B2 (ja) 2023-05-12
JP7760560B2 (ja) 2025-10-27
WO2019115386A1 (en) 2019-06-20
AU2018385257A1 (en) 2020-06-18
MX2020006246A (es) 2020-09-03
MX2025007909A (es) 2025-08-01
TWI911138B (zh) 2026-01-11
TW201936923A (zh) 2019-09-16
IL275217A (en) 2020-07-30
JP2023153970A (ja) 2023-10-18
CO2020007102A2 (es) 2020-06-19
BR112020011845A2 (pt) 2020-11-24
CN111801116A (zh) 2020-10-20
CA3085657A1 (en) 2019-06-20
PH12020550906A1 (en) 2021-05-17
KR102787688B1 (ko) 2025-03-27
AU2018385256B2 (en) 2025-09-25
EP4647437A2 (en) 2025-11-12
TW201936924A (zh) 2019-09-16
KR20200098638A (ko) 2020-08-20
CN111447949A (zh) 2020-07-24
RU2020122553A (ru) 2022-01-17
DOP2020000107A (es) 2020-08-31
CR20200260A (es) 2020-08-01
CN111447949B (zh) 2025-07-11
CN119656298A (zh) 2025-03-21
UY38014A (es) 2019-06-28
CL2020001562A1 (es) 2020-11-06
BR112020011838A2 (pt) 2020-11-24
DK3700564T3 (da) 2025-11-10
TWI900461B (zh) 2025-10-11
RU2020122545A (ru) 2022-01-19
PH12020550903A1 (en) 2021-05-17
CL2020001560A1 (es) 2020-11-06
US20210062192A1 (en) 2021-03-04
PE20210636A1 (es) 2021-03-23
UY38016A (es) 2019-06-28
EP3700564B1 (en) 2025-09-17
BR112020011815A2 (pt) 2020-11-17
JP7770769B2 (ja) 2025-11-17
AU2018385256A1 (en) 2020-06-11
AU2018382419B2 (en) 2025-04-10
AU2025205082A1 (en) 2025-07-31
EP3700564A1 (en) 2020-09-02
CL2020001561A1 (es) 2020-11-06
KR20200099556A (ko) 2020-08-24
US20230332162A1 (en) 2023-10-19
KR20200098637A (ko) 2020-08-20
MX2020006244A (es) 2020-09-03
US20210170020A1 (en) 2021-06-10
PL3700564T3 (pl) 2026-02-23
JP2021506779A (ja) 2021-02-22
WO2019115385A1 (en) 2019-06-20
CN120519464A (zh) 2025-08-22
PH12020550904A1 (en) 2021-05-17
JP2023156485A (ja) 2023-10-24
US11542507B2 (en) 2023-01-03
CN111801116B (zh) 2024-11-26
IL274975A (en) 2020-07-30
US20200385733A1 (en) 2020-12-10
PE20210635A1 (es) 2021-03-23
AU2025204678A1 (en) 2025-07-17
AU2018382419A1 (en) 2020-06-04
UY38015A (es) 2019-06-28
US20230174990A1 (en) 2023-06-08
SG11202004952UA (en) 2020-06-29
US12305173B2 (en) 2025-05-20
JP7458977B2 (ja) 2024-04-01
EP4647437A3 (en) 2026-02-18
WO2019115402A1 (en) 2019-06-20
MX2020006243A (es) 2020-09-03
SG11202004471RA (en) 2020-06-29
CO2020007120A2 (es) 2020-06-19
US20240076681A1 (en) 2024-03-07
CN111801419A (zh) 2020-10-20
CO2020007100A2 (es) 2020-06-19
EP3694549A1 (en) 2020-08-19
CA3085661A1 (en) 2019-06-20
DOP2020000106A (es) 2020-08-31
JP2021506246A (ja) 2021-02-22
AU2018385257B2 (en) 2025-04-10
IL275086A (en) 2020-07-30
JP2021506245A (ja) 2021-02-22
TW201940192A (zh) 2019-10-16

Similar Documents

Publication Publication Date Title
KR102787688B1 (ko) 면역자극성 올리고뉴클레오티드
ES2206424T3 (es) Oligodesoxinucleotidos inmunoestimulantes.
CN1604795B (zh) 具有提高的活性的组合基序免疫刺激寡肽
AU784403B2 (en) Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants
JP4188092B2 (ja) 免疫促進性オリゴデオキシ核酸分子
PT1511845E (pt) Oligonucleótidos imuno-estimuladores e suas utilizações
CN117050986B (zh) 具有免疫刺激活性的CpG寡聚核苷酸及其用途
WO2021178321A1 (en) Coronavirus vaccines comprising a tlr9 agonist
Adamsson et al. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin
Fasciano et al. Intervention of Toll-like receptor-mediated human innate immunity and inflammation by synthetic compounds and naturally occurring products
RU2790233C2 (ru) Иммуностимулирующие олигонуклеотиды
HK40033950A (en) Immunostimulatory oligonucleotides
Coffey et al. Therapeutic targeting of the innate immune system in domestic animals
Cheng et al. CpG oligodeoxynucleotide promotes protective immunity in the enteric mucosa and suppresses enterotoxigenic E. coli in the weaning piglets
Zeng et al. Delivery and immunologic efficacy of CpG ODN targeting B lymphocytes of umbilical cord blood by CD40 ligand-receptor-mediated carrier*☆
Park et al. The production and immunostimulatory activity of double-stranded CpG-DNA
Duvanov Selection of oligonucleotides specific to chicken peripheral blood mononuclear cells in whole blood ex vivo system

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250324

Application number text: 1020207020349

Filing date: 20200714

PA0201 Request for examination
PG1501 Laying open of application